Androgen receptor polymorphisms : Association with prostate cancer risk, relapse and overall survival.
Several reports have suggested that one or both of the trinucleotide repeat polymorphisms in the human androgen receptor (hAR) gene, (CAG) n coding for polyglutamine and (GGC) n coding for polyglycine, may be associated with prostate cancer risk ; but no study has investigated their association with disease progression.
We present here a study of both hAR trinucleotide repeat polymorphisms not only as they relate to the initial diagnosis but also as they are associated with disease progression after therapy.
Lymphocyte DNA samples from 178 British Caucasian prostate cancer patients and 195 control individuals were genotyped by PCR for the (CAG) nand (GGC) n polymorphisms in hAR.
Univariate Cox proportional hazard analysis indicated that stage, grade and GGC repeat length were individually significant factors associated with disease-free survival (DFS) and overall survival (OS).
The relative risk (RR) of relapse for men with more than 16 GGC repeats was 1.74 (95% CI 1.08-2.79) and of dying from any cause, 1.98 (1.13-3.45).
Adjusting for stage and grade, GGC effects remained but were not significant (RRDFS=1.60, p=0.052 ; RRos=1.65, p=0.088).
The greatest effects were in stage T1-T2 (RRDFS=3.56,95% Cl 1.13-11.21) and grade I (RRDFS=6.47,95% Cl 0.57-72.8) tumours.
No differences between patient and control allele distributions were found by odds-ratio analysis, nor were trends with stage or grade evident in the proportion of short CAG alleles. (...)
Mots-clés Pascal : Tumeur maligne, Prostate, Androgène, Récepteur hormonal, Récepteur biologique, Polymorphisme, Gène, Variabilité génétique, Récidive, Pronostic, Epidémiologie, Royaume Uni, Europe, Homme, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie, Génétique, Hormone stéroïde sexuelle
Mots-clés Pascal anglais : Malignant tumor, Prostate, Androgen, Hormonal receptor, Biological receptor, Polymorphism, Gene, Genetic variability, Relapse, Prognosis, Epidemiology, United Kingdom, Europe, Human, Male genital diseases, Urinary system disease, Prostate disease, Genetics, Sex steroid hormone
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0517400
Code Inist : 002B14D02. Création : 18/05/2000.